Cunning factor: Macrophage migration inhibitory factor as a redox-regulated target

Immunology and Cell Biology

Volumn 86, Issue 3, 2008, Pages 232-238

  Kudrin, Alex ^a,b   Ray, David ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cytokine; MIF; Oxidoreductase; Peroxiredoxin; Tautomerase; Thioredoxin

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; PEROXIREDOXIN; PHOSPHOTRANSFERASE; PROTEIN P53; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ENZYME ACTIVITY; GENETIC POLYMORPHISM; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ACETAMINOPHEN; ANIMALS; CELL MOVEMENT; DISEASE SUSCEPTIBILITY; FEEDBACK, BIOCHEMICAL; GLUCOCORTICOIDS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; REDUCING AGENTS; T-LYMPHOCYTES;

EID: 41149159156     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100133     Document Type: Review

References (102)

1. David J. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966; 56: 72-77.
2. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-82.
3. Kawaguchi T, Golde DW, Mednis A, Bersch N, Clark S, Remold HG. T cell-derived migration-inhibitory factor and colony-stimulating factor share common structural elements. Blood 1986; 67: 1619-1623.
4. Swope MD, Sun HW, Klockow B, Blake P, Lolis E. Macrophage migration inhibitory factor interactions with glutathione and S-hexylglutathione. J Biol Chem 1998; 273: 14877-14884.
5. Honma N, Koseki H, Akasaka T, Nakayama T, Taniguchi M, Serizawa I et al. Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia. Immunology 2000; 100: 84-90.
6. Lan HY, Mu W, Yang N, Meinhardt A, Nikolic-Paterson DJ, Ng YY et al. De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 1996; 149: 1119-1127.
7. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M et al. Macrophage migration inhibitory factor in rheumatoid arthritis - evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999; 42: 1601-1608.
8. Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158: 573-579.
9. Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998; 101: 2869-2874.
10. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999; 264: 751-758.
11. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 2004; 109: 380-385.
12. Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labelled MIF derivatives. J Interferon Cytokine Res 2002; 22: 351-363.
13. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure-analysis of mouse and human macrophage-migration inhibitory factor (MIF). Biochemistry 1994; 33: 14144-14155.
14. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68-71.
15. Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 2002; 277: 24976-24982.
16. Nguyen MT, Beck J, Lue H, Funfzig H, Kleemann R, Koolwijk P et al. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions. J Biol Chem 2003; 278: 33654-33671.
17. Senter PD, Al-Abed Y, Metz CN, Benigni F, Mitchell RA, Chesney J et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 2002; 99: 144-149.
18. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA et al. Development of chronic colitis is dependent on the cytokine MIF. Nature Immunol 2001; 2: 1061-1066.
19. Santos LL, Lacey D, Yang Y, Leech M, Morand EF. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004; 31: 1038-1043.
20. Onodera S, Nishihira J, Koyama Y, Majima T, Aoki Y, Ichiyama H et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 1437-1447.
21. Kudrin A, Scott M, Martin S, Chung CW, Donn R, McMaster A et al. Human macrophage migration inhibitory factor (MIF): a proven immunomodulatory cytokine? J Biol Chem 2006; 281: 29641-29651.
22. Sugie K, Tomura T, Takakura K, Kawano T, Taniguchi M, Grey HM et al. Target cells for an immunosuppressive cytokine, glycosylation-inhibiting factor. Int Immunol 1999; 11: 1149-1156.
23. Tomura T, Watarai H, Honma N, Sato M, Iwamatsu A, Kato Y et al. Immunosuppressive activities of recombinant glycosylation-inhibiting factor mutants. J Immunol 1999; 162: 195-202.
24. Watarai H, Nozawa R, Tokunaga A, Yuyama N, Tomas M, Hinohara A et al. Post-translational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. Proc Natl Acad Sci USA 2000; 97: 13251-13256.
25. Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M, Nishihira J. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 Å resolution. Biochemistry 1999; 38: 3268-3279.
26. Bendrat K, Al-Abed Y, Callaway DJE, Peng T, Calandra T, Metz CN et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 1997; 36: 15356-15362.
27. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998; 280: 85-102.
28. Sun HW, Swope M, Cinquina C, Bedarkar S, Bernhagen J, Bucala R et al. The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng 1996; 9: 631-635.
29. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and cell cycle through Jab1. Nature 2000; 408: 211-216.
30. Jung H, Kim T, Chae HZ, Kim KT, Ha H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J Biol Chem 2001; 276: 15504-15510.
31. Bulaj G, Kortemme T, Goldenberg DP. Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry 1998; 37: 8965-8972.
32. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T et al. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 2002; 99: 9745-9749.
33. Nickel W. The mystery of nonclassical protein secretion. Eur J Biochem 2003; 270: 2109-2119.
34. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-346.
35. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J et al. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 1996; 178: 179-185.
36. Okuyama H, Nakamura H, Shimahara Y, Araya S, Kawada N, Yamaoka Y et al. Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology 2003; 37: 1015-1025.
37. Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K et al. Redoxactive protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 2003; 168: 1075-1083.
38. Liu W, Nakamura H, Shioji K, Tanito M, Oka S, Ahsan MK et al. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004; 110: 1276-1283.
39. Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J et al. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998; 188: 1445-1451.
40. Bourdi M, Reilly TP, Elkahloun AG, George JW, Pohl LR. Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stress responsiveness. Biochem Biophys Res Commun 2002; 294: 225-230.
41. Ichiyama H, Onodera S, Nishihira J, Ishibashi T, Nakayama T, Minami A et al. Induction of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004; 26: 187-194.
42. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002; 4: 449-460.
43. Yodoi J, Nakamura H, Masutani H. Redox regulation of stress signals: possible roles of dendritic stellate TRX producer cells (DST cell types). Biol Chem 2002; 383: 585-590.
44. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33: 616-622.
45. Pekkari K, Gurunath R, Arner ES, Holmgren A. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 2000; 275: 37474-37480.
46. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 1999; 189: 1783-1789.
47. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad USA 2001; 98: 15143-15148.
48. Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-α-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol 1999; 163: 351-358.
49. Kondo N, Ishii Y, Son A, Sakakura-Nishiyama J, Kwon YW, Tanito M et al. Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 2004; 92: 143-147.
50. Takahashi M, Nishihira J, Shimpo M, Mizue Y, Ueno S, Mano H et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 2001; 52: 438-445.
51. Blocki FA, Schlievert PM, Wackett LP. Rat liver protein linking chemical and immunological detoxification systems. Nature 1992; 360: 269-270.
52. Nishihira J, Kuriyama T, Nishino H, Ishibashi T, Sakai M, Nishi S. Purification and characterization of human macrophage migration inhibitory factor: evidence for specific binding to glutathione and formation of subunit structure. Biochem Mol Biol Int 1993; 31: 841-850.
53. Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 1998; 1: 3534-3541.
54. Potolicchio I, Santambrogio L, Strominger JL. Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides. J Biol Chem 2003; 278: 30889-30895.
55. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 2002; 99: 1491-1496.
56. Inoue K, Couch EF, Takano K, Ogawa S. The structure and function of folliculo-stellate cells in the anterior pituitary gland. Arch Histol Cytol 1999; 62: 205-218.
57. Sido B, Giese T, Autschbach F, Lasitschka F, Braunstein J, Meuer SC. Potential role of thioredoxin in immune responses in intestinal lamina propria T lymphocytes. Eur J Immunol 2005; 35: 408-417.
58. Nordman T, Xia L, Bjorkhem-Bergman L, Damdimopoulos A, Nalvarte I, Arner ES et al. Regeneration of the antioxidant ubiquinol by lipoamide dehydrogenase, thioredoxin reductase and glutathione reductase. Biofactors 2003; 18: 45-50.
59. Damdimopoulos AE, Miranda-Vizuete A, Treuter E, Gustafsson JA, Spyrou G. An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling. J Biol Chem 2004; 279: 38721-38729.
60. Sakurai A, Yuasa K, Shoji Y, Himeno S, Tsujimoto M, Kunimoto M et al. Overexpression of thioredoxin reductase 1 regulates NF-kappa B activation. J Cell Physiol 2004; 198: 22-30.
61. Copley SD, Novak WRP, Babbitt PC. Divergence of function in the thioredoxin fold suprafamily: evidence for evolution of peroxiredoxins from a thioredoxin-like ancestor. Biochemistry 2004; 43: 13981-13995.
62. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signalling. Free Radic Biol Med 2005; 38: 1543-1552.
63. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004; 304: 596-700.
64. Kang SW, Chang TS, Lee TH, Kim ES, Yu DY, Rhee SG. Cytosolic peroxiredoxin attenuates the activation of JNK and p38 but potentiates that of ERK in HeLa cells stimulated with tumor necrosis factor-α. J Biol Chem 2004; 279: 2535-2543.
65. Pennock JL, Wipasa J, Gordge MP, Meyer DJ. Interaction of macrophage migration inhibitory factor with haematin. Biochem J 1998; 331: 905-908.
66. Hirotsu S, Abe Y, Okada K, Nagahara N, Hori H, Nishino T et al. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23kDa/proliferation-associated gene product. Proc Natl Acad Sci USA 1999; 96: 12333-12338.
67. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-myc and selectively alters its biological function and target gene expression. J Biol Chem 2002; 277: 43175-43184.
68. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 2005; 17: 225-236.
69. Chen X, Li Y, Wei K, Li L, Liu W, Zhu Y et al. The potentiation role of hepatopoietin on activator protein-1 is dependent on its sulfhydryl oxidase activity. J Biol Chem 2003; 278: 49022-49030.
70. Li Y, Li M, Xing G, Hu Z, Wang Q, Dong C et al. Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin. J Biol Chem 2000; 275: 37443-37447.
71. Li Y, Lu C, Xing G, Zhu Y, He F. Macrophage migration inhibitory factor directly interacts with hepatopoietin and regulates the proliferation of hepatoma cell. Exp Cell Res 2004; 300: 379-387.
72. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA et al. Migration inhibitory factor expression in experimentally induced endotoxinemia. Am J Pathol 1997; 150: 235-246.
73. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103: 588-598.
74. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002; 99: 345-350.
75. Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003; 100: 9354-9359.
76. Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K et al. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001; 7: 3430-3436.
77. Seemann S, Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 2005; 24: 3853-3863.
78. Wong CM, Chun AC, Kok KH, Zhou Y, Fung PC, Kung HF et al. Characterization of human and mouse peroxiredoxin IV: evidence for inhibition by Prx-IV of epidermal growth factor- and p53-induced reactive oxygen species. Antioxid Redox Signal 2000; 2: 507-518.
79. 2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100-18106.
80. Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 2005; 11: 1050-1058.
81. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003; 93: 321-329.
82. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-2606.
83. Cross JV, Templeton DJ. Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain. Biochem J 2004; 381: 675-683.
84. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I et al. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 1999; 274: 3182-3188.
85. Hirota K, Murata M, Sashi Y, Nakamura H, Takeuchi J, Mori K et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB. J Biol Chem 1999; 274: 27891-27897.
86. Hayashi S, Nakanishi KH, Makino Y, Eguchi H, Yodoi J, Tanaka H. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 1997; 25: 4035-4040.
87. Kleemann R, Rorsman H, Rosengren E, Mischke R, Mai NT, Bernhagen J. Dissection of the enzymatic and immunologic functions of macrophage migration inhibitory factor: full immunologic activity of N-terminally truncated mutants. Eur J Biochem 2000; 267: 7183-7193.
88. Asaba K, Iwasaki Y, Yoshida M, Asai M, Oiso Y, Murohara T et al. Attenuation by reactive oxygen species of glucocorticoid suppression on proopiomelanocortin gene expression in pituitary corticotroph cells. Endocrinology 2004; 145: 39-42.
89. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localisation of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995; 1: 781-788.
90. Tierney T, Patel R, Stead CA, Leng L, Bucala R, Buckingham JC. Macrophage migration inhibitory factor is released from pituitary folliculo-stellate-like cells by endotoxin and dexamethasone and attenuates the steroid-induced inhibition of interleukin 6 release. Endocrinology 2005; 146: 35-43.
91. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998; 4: 217-230.
92. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 1993; 365: 756-759.
93. Isidori AM, Kaltsas GA, Korbonits M, Pyle M, Gueorguiev M, Meinhardt A et al. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary adrenal axis in normal subjects and patients with Cushing's disease. J Clin Endocrinol Metab 2002; 87: 1834-1840.
94. Donn RP, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M et al. A functional promoter haplotype of macrophage migration inhibitory factor (MIF) is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004; 50: 1604-1610.
95. Lolis E, Bucala R. Macrophage migration inhibitory factor. Expert Opin Ther Targets 2003; 7: 153-164.
96. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-170.
97. Zhang X, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorg Med Chem Lett 1999; 9: 3193-3198.
98. Orita M, Yamamoto S, Katayama N, Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Des 2002; 8: 1297-1317.
99. Dios A, Mitchell RA, Aljabari B, Lubetsky J, O'Connor K, Liao H et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 2002; 45: 2410-2416.
100. Avanir Patent WO 2004/074218, PCT/US2004/004433.
101. Molnar V, Garai J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int Immunopharmacol 2005; 5: 849-856.
102. Sakamoto W, Nishihira J, Fujie K, Iizuka T, Handa H, Ozaki M et al. Effect of vitamin E on production of macrophage migration inhibitory factor (MIF) by macrophages. Biofactors 1999; 10: 139-143.